BriaCell wins FDA clearance to start Bria-PROS+ prostate cancer trial
BCTX•FDA clears Bria-PROS+ IND
- BriaCell won FDA clearance for its Bria-PROS+ IND, allowing a Phase 1/2a prostate cancer study to proceed.
- The program previously secured a USD 2 million non-dilutive grant from the US National Cancer Institute.
